{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:15:28Z","timestamp":1792786528112,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T00:00:00Z","timestamp":1413936000000},"content-version":"vor","delay-in-days":386,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Eugene Braunwald Endowment for the Advancement of Cardiovascular Discovery and Care","id":[{"id":"https:\/\/ror.org\/0229evh14","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AstraZeneca"},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Takeda","id":[{"id":"https:\/\/ror.org\/04hjbmv12","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fresenius","id":[{"id":"https:\/\/ror.org\/01v376g59","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005632","name":"Forest Laboratories","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005632","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.jacc.2013.04.086","type":"journal-article","created":{"date-parts":[[2013,6,27]],"date-time":"2013-06-27T09:03:53Z","timestamp":1372323833000},"page":"1585-1593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":222,"title":["Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and\/or Worsening Renal Function"],"prefix":"10.1016","volume":"62","author":[{"given":"Romain","family":"Eschalier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2013.04.086_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.04.086_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.04.086_bib3","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.04.086_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2013.04.086_bib5","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.04.086_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/eurjhf\/hfq049","article-title":"Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)","volume":"12","author":"Zannad","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2013.04.086_bib7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ki.1975.120","article-title":"Effect on aging on plasma renin and aldosterone in normal man","volume":"8","author":"Weidmann","year":"1975","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2013.04.086_bib8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajh.2008.152","article-title":"Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) activity in hypertensive patients","volume":"21","author":"Henschkowski","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jacc.2013.04.086_bib9","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/HYPERTENSIONAHA.109.148783","volume":"55","author":"Krug","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2013.04.086_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/pds.1923","article-title":"Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril","volume":"19","author":"Johnson","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacc.2013.04.086_bib11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurjhf\/hfs067","article-title":"Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"14","author":"Preiss","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2013.04.086_bib12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3109\/0886022X.2012.672156","article-title":"Mineralocorticoid receptor antagonist for renal protection","volume":"34","author":"Ma","year":"2012","journal-title":"Ren Fail"},{"key":"10.1016\/j.jacc.2013.04.086_bib13","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1046\/j.1523-1755.2000.00975.x","article-title":"Aldosterone and mineralocorticoid receptors: orphan questions","volume":"57","author":"Funder","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2013.04.086_bib14","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2013.04.086_bib15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2013.04.086_bib16","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure","volume":"60","author":"Vardeny","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.04.086_bib17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cardfail.2008.03.003","article-title":"Multiple neurohumoral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much?","volume":"14","author":"Mak","year":"2008","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2013.04.086_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.04.086_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.amjcard.2011.10.027","article-title":"Frequency and predictors of hyperkalemia in patients\u00a0\u226560 years of age with heart failure undergoing intense medical therapy","volume":"109","author":"Muzzarelli","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.04.086_bib20","doi-asserted-by":"crossref","first-page":"E890","DOI":"10.1016\/S0735-1097(12)60891-2","article-title":"Contemporary administration of aldosterone receptor antagonists in patients hospitalized with congestive heart failure after EMPHASIS-HF","volume":"59","author":"Chamsi-Pasha","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.04.086_bib21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/jama.2009.2","article-title":"BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial","volume":"301","author":"Pfisterer","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.04.086_bib22","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMp048144","article-title":"Treatment of heart failure with spironolactone\u2014trial and tribulations","volume":"351","author":"McMurray","year":"2004","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713025126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713025126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:02:53Z","timestamp":1760014973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713025126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":22,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0735109713025126"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2013.04.086","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and\/or Worsening Renal Function","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2013.04.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}